Table 3.
All grade 3–4 and most common grade 1–2 treatment-related adverse events
| Grade 1–2, n (%) | Grade 3–4, n (%) | All grades, n (%) | |
|---|---|---|---|
| Thrombocytopenia | 8 (47.1%) | 5 (29.4%) | 13 (76.5%) |
| Fatigue | 11 (64.7%) | --- | 11 (64.7%) |
| Nausea | 8 (47.1%) | 2 (11.8%) | 10 (58.8%) |
| Anemia | 8 (47.1%) | 2 (11.8%) | 10 (58.8%) |
| Elevated creatinine | 8 (47.1%) | --- | 8 (47.1%) |
| Leukopenia | 8 (47.1%) | --- | 8 (47.1%) |
| Lymphopenia | 4 (23.5%) | 3 (17.6%) | 7 (41.2%) |
| Hypophosphatemia | 4 (23.5%) | 3 (17.6%) | 7 (41.2%) |
| Neutropenia | 7 (41.2%) | --- | 7 (41.2%) |
| Diarrhea | 6 (35.3%) | --- | 6 (35.3%) |
| Anorexia | 4 (23.5%) | 1 (5.9%) | 5 (29.4%) |
| Hypoalbuminemia | 5 (29.4%) | --- | 5 (29.4%) |
| Vomiting | 4 (23.5%) | --- | 4 (23.5%) |
| Dizziness | 4 (23.5%) | --- | 4 (23.5%) |
| Myalgia | 4 (23.5%) | --- | 4 (23.5%) |
| Constipation | 4 (23.5%) | --- | 4 (23.5%) |
| Elevated alanine aminotransferase (ALT) | 4 (23.5%) | --- | 4 (23.5%) |
| Elevated alkaline phosphatase | 4 (23.5%) | --- | 4 (23.5%) |
| Weight loss | 2 (11.8%) | 1 (5.9%) | 3 (17.6%) |
| Elevated aspartate aminotransferase (AST) | 3 (17.6%) | --- | 3 (17.6%) |
| Impaired concentration | 3 (17.6%) | --- | 3 (17.6%) |
| Dry mouth | 3 (17.6%) | --- | 3 (17.6%) |
| Dysgeusia | 3 (17.6%) | --- | 3 (17.6%) |
| Headache | 3 (17.6%) | --- | 3 (17.6%) |
| Hyponatremia | 3 (17.6%) | --- | 3 (17.6%) |
| Cough | 2 (11.8%) | --- | 2 (11.8%) |
| Dehydration | 2 (11.8%) | --- | 2 (11.8%) |
| Limb edema | 2 (11.8%) | --- | 2 (11.8%) |
| Hypermagnesemia | 2 (11.8%) | --- | 2 (11.8%) |
| Hypernatremia | 2 (11.8%) | --- | 2 (11.8%) |
| Hypersomnia | 2 (11.8%) | --- | 2 (11.8%) |
| Elevated international normalized ratio (INR) | 2 (11.8%) | --- | 2 (11.8%) |
| Psychiatric disorder | --- | 1 (5.9%) | 1 (5.9%) |
| Thromboembolic event | --- | 1 (5.9%) | 1 (5.9%) |
| Hematuria | --- | 1 (5.9%) | 1 (5.9%) |